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release and antigen presentation
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Autoimmunity and macrophage recruitment into the central nervous system (CNS) are cri-
tical determinants of neuroinflammatory diseases. However, the mechanisms that drive
immunological responses targeted to the CNS remain largely unknown. Here we show that
fibrinogen, a central blood coagulation protein deposited in the CNS after blood–brain barrier
disruption, induces encephalitogenic adaptive immune responses and peripheral macrophage
recruitment into the CNS leading to demyelination. Fibrinogen stimulates a unique tran-
scriptional signature in CD11bþ antigen-presenting cells inducing the recruitment and local
CNS activation of myelin antigen-specific Th1 cells. Fibrinogen depletion reduces Th1
cells in the multiple sclerosis model, experimental autoimmune encephalomyelitis. Major
histocompatibility complex (MHC) II-dependent antigen presentation, CXCL10- and CCL2-
mediated recruitment of T cells and macrophages, respectively, are required for fibrinogen-
induced encephalomyelitis. Inhibition of the fibrinogen receptor CD11b/CD18 protects from
all immune and neuropathologic effects. Our results show that the final product of the
coagulation cascade is a key determinant of CNS autoimmunity.
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D
isruption of the homeostatic balance between the
vasculature and the brain is a sustained and often early
feature of neurologic diseases and traumatic insults to the
central nervous system (CNS). Understanding how blood–brain
barrier (BBB) disruption instigates and amplifies immune and
degenerative responses leading to brain pathology and loss of
function would be instrumental in the design of novel treatments
for neurologic diseases. Fibrinogen (coagulation factor I) is a
major component in the blood that upon BBB disruption enters
the CNS and is deposited as insoluble fibrin1. Although soluble
fibrinogen in the bloodstream is not proinflammatory, activation
of the coagulation cascade results in the formation of fibrin
associated with exposure of cryptic epitopes that transform
fibrinogen from a blood factor to a potent activator of innate
immunity1. In multiple sclerosis (MS) and experimental
autoimmune encephalomyelitis (EAE), BBB disruption and
fibrin deposition are detected in the white matter along with
microglial activation before T-cell infiltration and the onset of
demyelination2–6. Indeed, increased coagulation activity leading
to fibrin formation occurs early in neuroinflammation before
demyelination4, and is highly upregulated in active MS plaques7.
Moreover, injection of soluble fibrinogen in the healthy brain
results in fibrin formation5. Fibrin deposition is abundant not
only in early but also active and chronic MS lesions, and
correlates with demyelination and T-cell infiltration3,8–10. Genetic
or pharmacologic depletion of fibrinogen decreases microglial
activation and axonal damage and attenuates neurologic signs in
EAE5,7,11–13 and other MS models14,15. While studies in EAE
mice support a role for fibrin in the activation of microglia in
myelinated areas, its role in the initiation and propagation of
myelin-targeted adaptive immune responses is unknown.
Moreover, despite the vast literature on BBB disruption and
activation of the coagulation cascade in brain diseases, there is
currently no model of neuroinflammation induced by a
coagulation factor.
Here we developed a model of coagulation-driven demyelina-
tion to directly assess the role of BBB disruption and fibrin in the
induction of CNS autoimmunity and demyelination. Surprisingly,
introduction of fibrinogen into the healthy CNS was sufficient to
induce activation of adaptive immunity targeted to CNS myelin
antigens leading to demyelination. The effect of fibrinogen as an
initiator of CNS autoimmunity was first substantiated in vivo,
where a single stereotactic injection of fibrinogen in the corpus
callosum induced recruitment and local differentiation of myelin
antigen-specific Th1 cells leading to demyelination. In accor-
dance, endogenous fibrinogen was required for T-helper 1 (Th1)
cell activation in EAE. Microarray analysis in cell autonomous
systems of antigen-presenting cells (APCs) uncovered a unique
transcriptional signature for fibrin that links the coagulation
cascade with M1-type activation of APCs associated with
induction of antigen presentation and release of leukocyte
recruiting chemokines. Rescue experiments to genetically deplete
the fibrin-specific immune responses in APCs demonstrated that
secretion of the monocyte chemoattractant protein-1 (MCP-1/
CCL2) and the C-X-C motif ligand-10 (CXCL10), together with
MHC II-dependent antigen presentation, are essential molecular
mediators for fibrin-induced autoimmune responses in the CNS.
Furthermore, we showed that fibrin induces CNS autoimmune
responses not via its prohaemostatic functions, but due to
CD11b/CD18 receptor activation in APCs. Our results show for
the first time that a component of the coagulation cascade induces
autoimmunity, attributes the CNS effects of coagulation to the
proinflammatory effects of fibrin and introduces fibrinogen-
induced encephalomyelitis (FIE) as a novel coagulation-driven,
autoimmune-mediated model for the study of novel mechanisms
and therapies for brain inflammation.
Results
Fibrinogen in the CNS induces inflammatory demyelination.
To determine whether fibrinogen extravasation is sufficient to
induce CNS pathology in vivo, we stereotactically injected
fibrinogen at its physiological plasma concentration into the
corpus callosum, the largest CNS white matter tract associated
with disability in MS16. Surprisingly, this single injection of
fibrinogen spontaneously induced local demyelination within
7 days (Fig. 1a). Microglial activation was rapidly induced 1 day
after fibrinogen injection and preceded demyelination (Fig. 1a).
Activation of innate immunity regulates autoimmune responses
including T-cell recruitment and differentiation17,18. Fibrinogen
injection induced infiltration of both CD4þ and CD8þ T-cell
populations in the CNS, but not in the spleen (Fig. 1a,b;
Supplementary Fig. 1). T-cell infiltration occurred as early as
1 day after injection and markedly increased 3 and 7 days after
injection (Fig. 1a), thus also preceding demyelination. Injection of
fibrinogen in the spinal cord ventral column also induced
inflammatory demyelination (Supplementary Fig. 2). Neuro-
pathologic alterations were not observed after injection of control
artificial cerebrospinal fluid (ACSF) in either the brain or spinal
cord (Fig. 1; Supplementary Fig. 2). Although microglia show a
diffuse response in the cortex along the needle track 1 day after
ACSF injection, this response resolves and no alterations are
observed either in the cortex or the corpus callosum (Fig. 1).
While wild-type (WT) plasma induced demyelination similar
to fibrinogen, injection of plasma from fibrinogen-deficient
(Fib / ) mice19, which contains all plasma proteins except
fibrinogen, led to an 82% reduction in demyelination compared
with WT plasma (Supplementary Fig. 3). Injection of the plasma
proteins albumin or high-molecular-weight kininogen had no
effect (Supplementary Fig. 3).
Activation of the coagulation cascade converts fibrinogen to
proinflammatory fibrin primarily due to exposure of a cryptic
epitope in the fibrinogen g chain (g377–395), which binds to
CD11b/CD18 integrin (Mac-1, complement receptor 3,
aMb2)20,21. The interaction of fibrin with CD11b/CD18 is
genetically targeted in Fibg390–396A mice, in which fibrinogen
has been mutated to lack the CD11b/CD18-binding motif, but
retains normal clotting function22. Injection of plasma derived
from Fibg390–396A mice resulted in a 70% reduction in
demyelination compared with WT plasma (Supplementary
Fig. 3), suggesting that the interaction of fibrin with CD11b/
CD18 is required for the induction of demyelination. Since
a portion of fibrinogen in the plasma is known to bind
extracellular matrix proteins and growth factors, we also
produced and tested recombinant fibrinogen, which is clottable
and hydrodynamically indistinguishable from plasma fibrinogen,
with the exception that it did not carry other plasma-derived
factors23. Similar to plasma fibrinogen, recombinant fibrinogen
also induced demyelination and microglial activation
(Supplementary Fig. 4). These results suggest that fibrinogen is
a major component in the plasma that in the healthy CNS white
matter triggers T-cell recruitment and demyelination even in the
absence of pre-existing inflammatory or myelin abnormalities.
Fibrinogen induces M1-type activation of APCs. Genome-wide
microarray analysis either in the corpus callosum after fibrinogen
injection or in cell autonomous systems of fibrin-stimulated
microglia or bone marrow-derived macrophages (BMDMs)
revealed a unique fibrin transcriptional signature enriched
in genes regulating immune responses, particularly those
required to induce activation of T cells by APCs24, such as MHC
II, CD86 and IL-12, and recruitment of T cells and peripheral
macrophage into the CNS25–27, such as CXCL10 and CCL2
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(Fig. 2a–d; Supplementary Tables 1–3). Other immune response
genes, such as complement components, lipocalin and proteins
involved in iron binding and oxidative stress, were also increased.
Fibrin induced M1-type activation and induction of antigen-
presenting genes in both primary microglia and BMDMs (Fig. 2c;
Supplementary Fig. 5). Consistent with these findings, protein
and gene expression of MHC class II and CD86 were also induced
in fibrin-exposed BMDMs, and were inhibited by anti-CD11b
treatment (Fig. 2d; Supplementary Fig. 6). Lipopolysaccharide
(LPS) was used as a positive control (Fig. 2d; Supplementary
Fig. 6). In agreement, fibrinogen injection in the corpus callosum
induced MHC class II and CXCL10 in Iba-1þ cells
(Supplementary Fig. 7a,b). Similar to fibrinogen, injection of
WT plasma in the corpus callosum induced CXCL10 expression,
while plasma derived from Fib / or Fibg390–396A mice showed
a significant reduction (Supplementary Fig. 7c). Strikingly, MHC
II / (ref. 28), Cxcl10 / (ref. 29) and RAG2 / gc /
(ref. 30) mice, which lack T, B and natural killer cells, had a
marked reduction in demyelination after fibrinogen injection
compared with WT mice (Fig. 2e). Cxcl10 / mice also had 54%
less T-cell infiltration than WT mice after fibrinogen injection
(Supplementary Fig. 8). Overall, these results suggest that fibrin is
a potent activator of APCs that triggers demyelination via T-cell
recruitment into the CNS.
Fibrinogen promotes recruitment of encephalitogenic T cells.
To examine whether fibrinogen could induce T-cell responses
against myelin antigens in vivo, we tested its effects in 2D2
transgenic mice constitutively expressing T-cell antigen receptors
(TCRs) specific for myelin oligodendrocyte glycoprotein
(MOG)31. After fibrinogen injection in the corpus callosum,
T-cell infiltration and demyelination in 2D2 mice were 46% and
51% higher, respectively, compared with WT mice (Fig. 3a). In
contrast, in control OT-II transgenic mice constitutively
expressing TCRs specific for ovalbumin (OVA), an antigen not
present in the CNS32, T-cell infiltration after fibrinogen injection
was 77% and 66% less than in 2D2 or WT mice, respectively
(Fig. 3a). Consistent with this result, demyelination was also
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Figure 1 | Induction of T-cell recruitment and inflammatory demyelination by a single fibrinogen injection in the CNS. (a) Demyelination (LFB/PAS and
toluidine blue), microglial activation and demyelination (MBP/Iba-1), and T-cell infiltration (CD3) in the corpus callosum of mice injected with fibrinogen
compared with ACSF control. Scale bar, 100 mm (top panel); 10 mm (second panel); 100 mm (third panel); 80 mm (bottom panel). Representative histological
sections from day 7 after injection are shown. Data are presented as mean±s.e.m. (n¼ 5–6 mice per time point). *Po0.05, ***Po0.001, ****Po0.0001
(two-way ANOVA and Bonferroni’s multiple comparisons test). (b) FACS analysis of T cells isolated from the brain (corpus callosum) 7 days after
fibrinogen or ACSF injection stained with CD3, CD4 and CD8 (n¼ 3 independent experiments; each experiment generated from pooled brain cells from
n¼ 3–4 mice). ANOVA, analysis of variance; d, days; FACS, fluorescence-activated cell sorting; LFB, Luxol fast blue.
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Figure 2 | Adaptive immunity and antigen presentation are required for fibrinogen-induced demyelination. (a) Affymetrix microarray gene expression
analysis and enrichment of gene ontology (GO) of fibrinogen-injected or ACSF-injected corpus callosum at 12 h post injection. Heatmaps of the 142 genes
with Z1.5 change in expression between ACSF and fibrinogen. (b) Affymetrix microarray gene expression analysis of fibrin-stimulated rat primary
microglia at 6 h in vitro. Heatmap and GO analysis of gene expression profiles of 1,342 genes withZ1.5 change in expression between unstimulated and
fibrin treatment. (c) Affymetrix microarray gene expression analysis of fibrin-stimulated mouse APCs at 6 h in vitro. Heatmap and GO analysis of gene
expression profiles of key genes withZ1.5 change in expression (left). Heatmap of the M1-related genes withZ2.0 change in expression after fibrin
stimulation (right). (d) FACS analysis of CD86 expression in APCs after fibrin stimulation. LPS was used as positive control. Anti-CD11b antibody treatment
reduces CD86 expression in APCs. Real-time PCR analysis of CD86 gene expression in BMDMs after fibrin stimulation treated with anti-CD11b or IgG
isotype control antibody. Data are presented as mean±s.e.m. (n¼4 independent experiments; right). **Po0.01, ***Po0.001, ****Po0.0001 (one-way
ANOVA). (e) Demyelination (LFB/PAS) in the corpus callosum of WT, MHC II / or RAG2 /gc / mice 7 days after fibrinogen injection.
Representative images are shown. Scale bar, 100mm. Data are presented as mean±s.e.m. (n¼ 6 mice per group). **Po0.01, ***Po0.001 (one-way
ANOVA and Bonferroni’s multiple comparisons test). ANOVA, analysis of variance; FACS, fluorescence-activated cell sorting; LFB, Luxol fast blue.
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significantly reduced in OT-II mice (Fig. 3a). Fibrin-treated
BMDMs significantly increased the proliferation of MOG35–55-
treated CD4þ2D2 T cells in a CD11b-dependent manner, further
suggesting that fibrin-induced activation of APCs promotes
myelin-specific T-cell activation (Fig. 3b). LPS was used as a
positive control (Fig. 3b).
Fibrinogen promotes CNS expansion of encephalitogenic T cells.
In addition to macrophages, microglia contribute to antigen
presentation and T-cell activation during CNS autoimmune
diseases33. This prompted us to investigate whether fibrin-induced
microglial activation also influenced the activation of
encephalitogenic T cells. Co-culture of microglia with naive 2D2
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callosum of WT, 2D2 and OT-II mice 7 days after fibrinogen injection. Scale bars, 100mm (top panel); 200mm (bottom panel). Quantification of CD3þ Tcells
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****Po0.0001 by one-way ANOVA and Bonferroni’s multiple comparisons test. (b) BMDMs treated with fibrin alone or in the presence of anti-CD11b or
isotype IgG antibody control were co-cultured with naive 2D2 CD4þ Tcells. BrdU proliferation assay in response to MOG35–55 peptide after fibrin stimulation
and anti-CD11b treatment. LPS was used as positive control. Data are presented as mean±s.e.m. (n¼ 3–4 independent experiments, *Po0.05, **Po0.01 by
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compared with fibrin and OVA323–339 or MOG35–55 alone. Data are presented as mean±s.e.m. (n¼4 mice per group, *Po0.05 by non-parametric
Mann–Whitney U-test). ANOVA, analysis of variance; d, days; FACS, fluorescence-activated cell sorting; LFB, Luxol fast blue.
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T cells in the presence of MOG peptide increased antigen-specific
cell proliferation (Supplementary Fig. 9). Importantly, fibrin-
stimulated microglia were more efficient APC for
encephalitogenic T-cell proliferation than unstimulated microglia
(Supplementary Fig. 9). On the basis of these findings, we
asked whether fibrin induced activation of encephalitogenic T
cells in the CNS. We labelled naive MOG-specific 2D2 T cells with
carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor
lymphocyte proliferation in vivo34,35. CFSE-labelled 2D2 T cells
were adoptively transferred into fibrinogen- or control ACSF-
injected WT mice and donor T cells were reisolated from the
brain at 6 days after the transfer (Fig. 3c). MOG-specific 2D2 T cells
proliferated in the brains of fibrinogen-injected recipients,
compared with ACSF-injected controls (Fig. 3c), suggesting
local T-cell activation. We next examined whether fibrin-induced
activation of APCs promotes encephalitogenic T-cell trafficking into
the CNS. Naive 2D2 or control OT-II T cells were
co-cultured with BMDMs in the presence of MOG35–55 or
OVA323–339, respectively. We adoptively transferred stimulated
2D2 or OT-II T cells into Rag1 / recipients that
had been injected with fibrinogen and assessed migrated
T cells in the corpus callosum after 3 days. Accumulation of 2D2
T cells in the corpus callosum was observed when
donor 2D2 T cells were stimulated with their cognate antigen in
the presence of fibrin-treated BMDMs, compared with only
MOG35–55-treated cells (Fig. 3d). In contrast, fibrin-stimulated
BMDMs did not promote the accumulation of OT-II T cells in the
corpus callosum of Rag1 / recipients that had been injected with
fibrinogen (Fig. 3d). These results suggest that
fibrin signalling via CD11b/CD18 primes APCs, which facilitates
the local expansion of antigen-specific encephalitogenic T cells
within the CNS.
Fibrinogen activates endogenous myelin antigen-specific T cells.
Local CNS activation of antigen-specific T cells in the brain
drives autoimmune reactions18,36. Using the I-Ab MOG35–55
tetramer to detect in situ myelin-specific CD4þ T cells37,38, we
examined whether fibrinogen entry in the CNS induces the
local activation of myelin antigen-specific T cells. After 7 days
post injection, isolated lymphocytes from draining lymph
nodes were cultured with MOG35–55 peptide (Fig. 4a). Ex vivo
staining with MOG35–55 tetramer of cells from draining
lymph nodes showed a small but detectable fraction of tetramer-
positive CD4 T cells only in fibrinogen-injected, but not in ACSF-
injected mice. No tetramer-positive cells were detected on
incubation with control I-Ab OVA323–339 tetramer (Fig. 4b),
suggesting that fibrinogen induced myelin antigen-specific T-cell
activation. Interestingly, only CD4þ T cells isolated from the
cervical lymph nodes of fibrinogen-injected, but not ACSF-injected
mice showed increased bromodeoxyuridine (BrdU) incorporation
on MOG35–55 stimulation (Fig. 4c). To examine T-cell responses in
the SJL/J mouse strain, lymphocytes were isolated from draining
lymph nodes of fibrinogen-injected SJL/J mice and cultured
with different proteolipid protein (PLP) peptides, including
PLP139–151 and PLP178–191, which are immunodominant epitopes
in the SJL/J mouse strain. CD4þ T cells of fibrinogen-injected SJL/
J mice did not show significant proliferation in response to PLP139–
151 or to ACSF (Supplementary Fig. 10), suggesting that perhaps
isolation and expansion of a higher number of T cells from the
draining lymph node and the CNS would be required to study
responses to other myelin antigens after induction of FIE in other
strains. In our study, MOG35–55 tetramer binding (Fig. 4b) and
MOG35–55-induced BrdU incorporation (Fig. 4c) demonstrate
the presence of functional autoreactive myelin antigen-specific
CD4þ T cells in mice with fibrinogen-induced inflammatory
demyelination.
Fibrin induces Th1-cell differentiation via CD11b/CD18. T-cell
differentiation into either Th1 or Th17 cells is central to the
induction of autoimmune demyelination, and is pertinent to MS
pathogenesis39,40. In a co-culture system of CD4þ T cells with
BMDMs stimulated with a fibrin preparation, we observed
elevated expression of Th1 (T-bet), but not Th2 (Gata-3) or Th17
(Rorc) transcription factors (Fig. 5a). In accordance, the
frequency of interferon-g (IFN-g)þCD4þ T cells, but not
interleukin (IL)-4þCD4þ T cells, was higher when co-cultured
with fibrin-stimulated BMDMs (Fig. 5b). Treatment of fibrin-
stimulated BMDMs with an antibody against CD11b (M1/70)
reduced the frequency of IFN-gþ CD4þ T cells and the gene
expression of IFN-g compared with treatment with isotype
control antibody (Fig. 5b). Fibrin stimulation of BMDMs
increased expression of the Th1-promoting cytokine IL-12p40
(ref. 41), which was markedly blocked by anti-CD11b treatment
(Fig. 5b). Co-culture of BMDMs stimulated with kininogen did
not induce Th1-cell differentiation (Supplementary Fig. 11).
Introduction of fibrinogen in the CNS increased expression of the
Th1 transcription factor, T-bet, but not the Th2, Th17 or
regulatory T-cell transcription factors, Gata-3, Rorc and FoxP3,
respectively (Fig. 5c). In accordance, fibrinogen injection
increased gene expression of the Th1 cytokine IFN-g and
IL-12p40, while it had no effect on the expression of IL-4 (Th2)
and IL-17F (Th17) (Fig. 5c). T cells isolated from the fibrinogen-
injected corpus callosum also displayed increased IFN-g-
expressing cells among infiltrated CD4þ and CD8þ T cells by
6.19- and 28.2-fold, respectively (Fig. 5d). In contrast, fibrinogen
injection did not significantly increase the number of IL-4þ or
IL-17þ in CD4þ and CD8þ T cells as compared with ACSF
injection (Fig. 5d). Fibrinogen induced local Th1 polarization
specifically in the brain, as no changes were observed in the
spleen (Fig. 5d). In accordance, depletion of fibrinogen in EAE
reduced the number and proliferation of IFN-gþ T cells, while
no effects were observed in IL-4þ T cells (Fig. 5e). Overall, these
findings introduce the novel concept that a plasma-derived
coagulation factor, fibrinogen, may be a key molecular pathway to
selectively induce release of Th1-polarizing cytokines in APCs
and increase the effector function of encephalitogenic T cells.
Fibrinogen induces macrophage recruitment into the CNS.
Recruitment of CCR2þ peripheral monocytes regulate the
severity of demyelination26,42, and are essential for EAE
progression to paralytic disease43,44. We injected fibrinogen into
Ccr2RFP/þCx3cr1GFP/þ mice, which differentially label resident
microglia (green fluorescent protein (GFP) positive (GFPþ ),
green) and inflammatory monocytes (red fluorescent protein
(RFP) positive (RFPþ ), red)42. RFPþ cells were detected
at 3 days after injection and their numbers remained elevated at
7 days after injection (Fig. 6a). GFPþ cells rapidly accumulated
1 day after fibrinogen injection and gradually increased
up to 7 days post injection (Fig. 6a), suggesting that microglial
activation preceded peripheral macrophage cell infiltration.
No RFPþ cells were found in the corpus callosum after ACSF
injection. These results suggest that in addition to T-cell
infiltration, extravascular fibrinogen also triggers recruitment of
inflammatory monocytes into the CNS.
Fibrinogen increased Ccl2 in the corpus callosum in vivo, and
after stimulation of primary microglia and APCs (Fig. 2a–c).
Interestingly, the local upregulation of CCL2 appeared to be
instrumental in FIE. Indeed, peripheral macrophage recruitment,
T-cell infiltration and demyelination were reduced following
fibrinogen injection into Ccr2RFP/RFP mice lacking the CCL2
receptor (Fig. 6b). Like purified fibrinogen, WT plasma was a
potent inducer of Ccl2 and Cxcl10 expression, whereas injection of
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either Fib / or Fibg390-396A plasma resulted in their significant
reduction (Fig. 6c; Supplementary Fig. 7c). Overall, these results
suggest that fibrinogen-induced upregulation of Ccl2 via CD11b/
CD18 facilitates the recruitment of peripheral macrophages and
contributes to the induction of inflammatory demyelination.
CD11b inhibition rescues the fibrinogen CNS effects. To
further examine whether CD11b/CD18 signalling is required for
fibrinogen-induced demyelination, we injected fibrinogen into the
corpus callosum of CD11b-deficient mice (Itgam / )45.
Microglial activation, T-cell infiltration, demyelination and
expression of Cxcl10, Ccl2, T-bet, IFN-g and IL-12p40 were
significantly decreased in Itgam / mice after fibrinogen
injection, compared with WT (Fig. 7), suggesting the
requirement for CD11b/CD18 signalling in fibrinogen-induced
adaptive immune activation. Expression of OX-40, a co-
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Figure 4 | Fibrinogen drives accumulation of myelin antigen-specific T cells. (a) Experimental design diagram: C57BL/6 mice were stereotaxically
injected with fibrinogen or ACSF in the corpus callosum. Seven days after injection, lymphocytes were prepared from draining lymph nodes and stimulated
with MOG35–55 for 7 d. I-A
b MOG35–55 tetramer was used to detect myelin-specific CD4
þ Tcells in fibrinogen-injected WTmice. I-Ab OVA323–339 tetramer
was used as a negative control for MOG35–55 tetramer staining. (b) Flow cytometry analysis of I-A
b MOG35–55 tetramer stained CD4
þ Tcells 7 days after
MOG35–55 stimulation. No tetramer-positive cells were detected with I-A
b OVA323–339 tetramer. Graph shown number of I-A
b MOG35–55 tetramer stained
CD4þ T cells. Data are presented as mean±s.e.m., n¼8–9, with each sample being pooled from 2–3 mice from three independent experiments.
***Po0.001 (non-parametric Mann–Whitney U-test). (c) Proliferation analysis of BrdU incorporation in CD4þ T cells of ACSF- and fibrinogen-injected
mice, stimulated with MOG35–55 for 7 days. Data are presented as mean±s.e.m. (four independent experiments with pooled cells from 2–3 mice per
experiment for ACSF and fibrinogen), *Po0.05 (non-parametric Mann–Whitney U-test). d, days.
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Figure 5 | Fibrin induces activation of innate immunity via CD11b/CD18 to induce Th1-cell differentiation. (a) BMDMs treated with fibrin or in the
presence of anti-CD11b or isotype IgG antibody control were co-cultured with naive WT CD4þ Tcells and analysed for gene expression or by FACS. Gene
expression analysis of transcriptional factors indicative of Th1, Th2, Th17 and Treg cells in CD4
þ Tcells co-cultured with fibrin-stimulated BMDMs. Data are
presented as mean±s.e.m. (n¼4 independent experiments, *Po0.05 by non-parametric Mann–Whitney U-test). (b) Gated percentage of IFN-g- or
IL-4-expressing CD4þ T cells after co-culture with fibrin-stimulated BMDMs in the presence of rat IgG isotype control antibody or anti-CD11b antibody.
Data are presented as mean±s.e.m. (n¼ 3 independent experiments, *Po0.05, **Po0.01, ***Po0.001 by one-way ANOVA and Bonferroni’s multiple
comparisons test). Real-time PCR analysis of Th1-inducing cytokine IL-12p40 in fibrin-stimulated BMDMs in the presence or absence of anti-CD11b
antibody. Data are presented as mean±s.e.m. (n¼ 3–4 independent experiments, *Po0.05, **Po0.01 by one-way ANOVA and Bonferroni’s multiple
comparisons test). (c) Real-time PCR analysis of transcription factors and cytokines indicative of Th1, Th2, Th17 and Treg cells in the corpus callosum at
3 days after ACSF or fibrinogen injection. Data are presented as mean±s.e.m. (n¼ 3–5 mice per group). *Po0.05 (non-parametric Mann–Whitney
U-test). (d) Comparison of IFN-g-, IL-4- and IL-17-producing cells in infiltrated CD4þ and CD8þ Tcells isolated from the brains and spleens after ACSF or
fibrinogen injection at day 7 post injection. Data are presented as mean±s.e.m. (n¼ 3 independent experiments, *Po0.05, ***Po0.001 by one-way
ANOVA and Bonferroni’s multiple comparisons test). (e) IFN-g and IL-4 expression in CD4þ lymph node T cells isolated from saline- or fibrin-depleted
(ancrod) mice after PLP139–151-induced EAE and restimulated in vitro with PLP139–151. Data are presented as mean±s.e.m. (n¼ 6 mice per group, *Po0.05,
**Po0.01 by non-parametric Mann–Whitney U-test). ANOVA, analysis of variance; FACS, fluorescence-activated cell sorting; Treg, regulatory T cell.
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stimulatory molecule expressed in activated T cells46, increased
by B30-fold is on CNS-infiltrating T cells after fibrinogen
injection (Fig. 8a). OX-40-labelled T-cell activation was
significantly reduced in Itgam / mice after fibrinogen
injection by B60% (Fig. 8a), suggesting that fibrinogen induces
local CNS T-cell activation in a CD11b-dependent manner.
Consistent with these results, in mice challenged by fibrinogen
injection into the corpus callosum pharmacologic inhibition of
CD11b by intracerebroventricular delivery of M1/70 reduced
expression of Cxcl10 and Ccl2 (Fig. 8b), and decreased T-cell and
peripheral macrophage infiltration (Fig. 8c), when compared with
isotype control IgG-treated cohorts. Taken together, these data
suggest that the introduction of fibrinogen into CNS tissues
induces peripheral immune cell recruitment, T-cell activation and
demyelination via a CD11b/CD18-dependent mechanism.
Discussion
This study establishes the fundamental role of the coagulation
cascade as a driver of adaptive immune responses and the
mechanisms by which extravasation of a blood clotting factor into
the brain white matter can induce autoimmunity, demyelination
and peripheral macrophage recruitment into the CNS. Our results
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suggest that fibrin, the final product of the coagulation cascade,
constitutes a sustained, non-diffusible and geographically con-
strained immunological molecular switch that triggers the
inopportune local activation of resident APCs to induce the
proliferation, recruitment and local activation of myelin antigen-
specific Th1 cells in the CNS. The introduction of fibrinogen in
myelinated areas in the healthy CNS led to the four major
findings (Fig. 8d): (i) fibrinogen leakage in the CNS is a major
plasma protein that induces CNS autoimmune responses and
demyelination; (ii) fibrinogen is a key inducer of recruitment of
both encephalitogenic T cells and peripheral macrophages into
the CNS via CXCL10 and CCL2 chemokine secretion, respec-
tively; (iii) activation of the coagulation cascade in the CNS
favours Th1-cell differentiation via fibrin-induced upregulation of
IL-12; and (iv) the effects of coagulation to CNS autoimmunity
are primarily due to the proinflammatory, CD11b-mediated
effects of fibrin, thus dissecting the beneficial prohaemostatic
roles of coagulation from its damaging effects in CNS disease.
Fibrinogen is not only sufficient to induce T-cell activation and
demyelination in the healthy CNS, but is also required for T-cell
activation after peripheral autoimmune activation as shown on
depletion of endogenous fibrinogen in EAE. These new findings,
together with our prior studies in EAE showing (i) early
activation of coagulation4 and (ii) reduction of neurological
signs, microglial activation, demyelination and axonal damage on
fibrinogen depletion5,11,14, bolster the significance of coagulation
activity in the development of neuroinflammatory lesions and
establish fibrinogen as a key component of the coagulation
cascade with pleiotropic functions in CNS innate and adaptive
immunity.
In EAE, T cells enter the CNS after local activation by
perivascular macrophages at the leptomeninges and their initial
local CNS activation determines the clinical outcome of the
autoimmune response18. Fibrin is localized in the leptomeninges at
EAE pre-onset and induces early perivascular clustering of
microglia and meningeal macrophages5. Moreover, in marmoset
EAE early BBB leakage is associated with perivascular inflam-
matory cuffing and parenchymal microglial activation, but
precedes demyelination6. Therefore, it is possible that within the
CNS fibrin functions as an instructive signal enabling antigen-
presenting properties in resident perivascular macrophages and
thus facilitating T-cell entry, proliferation and activation. MOG35–
55 tetramer binding in the cervical lymph nodes (Fig. 4b) and
MOG35–55-induced BrdU incorporation (Fig. 4c) demonstrate the
presence of functional autoreactive myelin antigen-specific CD4þ
T cells in C57BL/6 mice injected with fibrinogen in the corpus
callosum. Future studies will characterize the responses of T cells
to other myelin antigens of not only C57BL/6 mice, but also in the
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Figure 7 | Genetic inhibition of CD11b blocks fibrinogen-induced microglial activation and inflammatory demyelination. (a) Quantification of microglial
activation (IBA-1), T-cell infiltration (CD3) and demyelination (LFB/PAS) 7 days after fibrinogen injection in the corpus callosum of Itgam / or control
WTmice (n¼6). Data are presented as mean±s.e.m. *Po0.05, **Po0.01 (non-parametric Mann–Whitney U-test). (b) Fibrinogen-induced gene
expression of Cxcl10 and Ccl2 is reduced in the corpus callosum of Itgam / mice compared with WTcontrol. Results are mean±s.e.m. of 6–7 mice per
group, **Po0.01, ****Po0.0001 (two-way ANOVA and Bonferroni’s multiple comparisons test). (c) Fibrinogen-induced gene expression of T-bet, IFN-g
and IL-12p40 is reduced in the corpus callosum of Itgam / mice compared with WT control (n¼ 5–8 mice). Data are presented as mean±s.e.m.
**Po0.01, ***Po0.001 (two-way ANOVA and Bonferroni’s multiple comparisons test). ANOVA, analysis of variance; d, days; LFB, Luxol fast blue.
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CNS and draining lymph nodes of other mouse strains. Since
interactions of T cells with APCs also continue during the peak of
EAE18, fibrin-induced activation of autoimmune responses might
play a role not only at the onset but also for the amplification and
perpetuation of the autoimmune response.
Strikingly, our study shows that extravascular fibrinogen
induces a transcriptional program of immune effector–cell
activation and recruitment that links innate with adaptive
immunity. Upregulation of CXCL10 and IL-12p40, two immune
modulators involved in T-cell recruitment and Th1-cell differ-
entiation, occurs before the infiltration of peripheral leukocytes,
suggesting that fibrinogen-induced activation of CNS innate
immunity appears to be a primary pathogenic event that precedes
T-cell entry into the CNS. Since CCL2-dependent recruitment of
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Figure 8 | Inhibition of CD11b blocks fibrinogen-induced local T-cell activation, chemokine gene expression and peripheral inflammatory cell
recruitment. (a) Fibrinogen-induced local T-cell activation (OX-40) in the corpus callosum of WTmice is significantly reduced in Itgam / mice (n¼4).
Representative images are shown. Data are presented as mean±s.e.m. **Po0.01, ***Po0.001 (one-way ANOVA and Bonferroni’s multiple comparisons
test). Scale bar, 100mm. (b) In vivo pharmacologic blockade of CD11b by intracerebroventricular delivery of anti-CD11b antibody reduces fibrinogen-induced
Cxcl10 and Ccl2 gene expression, compared with isotype IgG control antibody. Data are presented as mean±s.e.m. (n¼ 5 per group). *Po0.05, **Po0.01,
***Po0.001 (one-way ANOVA and Bonferroni’s multiple comparisons test). (c) Quantification of infiltrated CD3þ T cells and RFPþ macrophages in the
corpus callosum 7 days after injection of fibrinogen in WTmice treated with anti-CD11b or IgG isotype control antibody. Data are presented as
mean±s.e.m. (CD3, n¼ 6–7 mice per group; RFP, n¼ 7 mice per group). *Po0.05, **Po0.01 (non-parametric Mann–Whitney U-test). (d) Proposed
model for the role of fibrin, the final product of the coagulation cascade, in the development of CNS autoimmunity. On BBB disruption, fibrinogen
extravagates into the CNS and is converted to fibrin upon activation of coagulation. Fibrin, the high-affinity plasma-derived ligand for CD11b/CD18,
activates CNS resident innate immune cells (microglia and perivascular macrophages) to stimulate chemokine release leading to recruitment of peripheral
inflammatory macrophages/monocytes and T cells. Fibrin also induces antigen-presenting properties and provides instructive signals (such as IL-12) for
inducing Th1-cell differentiation. Fibrin-induced microglial activation, recruitment of peripheral macrophages and T-cell activation lead to inflammatory
demyelination. ANOVA, analysis of variance.
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peripheral monocytes is required for antigen-specific Th1
immune responses26, fibrin-induced recruitment of peripheral
monocytes might contribute to Th1-cell differentiation. Indeed,
the fibrin-induced IL-20p40 expression in both microglia and
BMDMs observed here suggests that both resident and peripheral
CD11bþ innate immune cells can be activated by fibrin to enable
autoimmune responses. Therefore, an attractive scenario based
on the present findings is that weakening of the BBB either by
peripheral brain autoimmune response or by exposure to high-
risk environmental factor(s) that weaken the BBB, such as
systemic inflammation and infection, extravascular fibrin
deposition and activation of coagulation in the CNS might be
key upstream signals for the activation of innate and adaptive
immune responses.
The time-course study in Ccr2RFP/þCx3cr1GFP/þ mice showed
that the primary effect of fibrinogen is on the resident GFPþ
microglia and secondarily on the peripheral RFPþ macrophages
(Fig. 6). Indeed, morphologic changes in GFP-expressing
microglia occur as early as 1 day after fibrinogen injection, while
RFP-expressing macrophages are not detected in the CNS until
3 days after fibrinogen injection (Fig. 6a). Accordingly, increased
chemokine gene expression in the corpus callosum is detected as
early as 12 h after fibrinogen injection (Fig. 2a), before the
infiltration of peripheral macrophages (Fig. 6a) and T cells
(Fig. 1a). Notably, pharmacologic inhibition of CD11b in the CNS
by intracerebroventricular delivery of M1/70 reduced chemokine
expression and decreased peripheral macrophage infiltration
(Fig. 8b,c), further suggesting that microglia are the primary cell
target of fibrinogen in vivo. CD11b/CD18 is expressed in
microglia and macrophages and regulates myelin phagocytosis11.
It is possible that CD11b/CD18 engagement of extravascular
fibrinogen induces activation of APC properties in innate
immune cells in a hierarchical manner, first by activating
microglia and then peripheral macrophages after they enter the
CNS. Since peripheral macrophages enter into the CNS in
neurodegenerative diseases associated with BBB and fibrin
deposition, such as stroke and Alzheimer’s disease47, fibrinogen
might stimulate the recruitment of peripheral macrophages into
the CNS in a wide spectrum of neurological diseases.
We established FIE as a novel experimental setting for
exploring the cascade of pathogenic events that directly follow
from the leakage of plasma proteins in the white matter in the
absence of pre-existing peripheral immune activation or myelin
pathology. We selected stereotactic delivery of fibrinogen as it is a
common experimental method in viral- and toxin-induced
demyelination48, as well as in established neurodegeneration
models, such as kainic acid injection in the hippocampus.
Moreover, stereotactic delivery evades any complexities
associated with the imposed genetic expression, assembly and
processing of all three chains of fibrinogen. FIE could be used to
dissect the contribution of BBB disruption and the coagulation
cascade in the CNS without the confounding factors of pre-
existing viral, cytokine, toxin or autoimmune events. Given its
rapid 7-day disease course, FIE could also be used as a
pharmacodynamic model to rapidly test the efficacy of novel
treatments for inhibiting CNS-targeted innate and adaptive
immune responses. Using albumin, kininogen and plasma
derived from Fib / and Fibg377-395 mice, we show that
fibrinogen is a major protein in the blood that drives sustained
neuroinflammatory responses in the CNS. It is possible that in
addition to fibrinogen, other plasma proteins might play a role in
brain pathology. In particular, other components of the
coagulation cascade involved in fibrin formation and clot
stabilization, such as thrombin, factors X, XII and XIII could be
involved in inflammatory responses49. Future studies will
elucidate the relative contribution of blood proteins to brain
inflammation and neurodegeneration. Our study demonstrates
that fibrinogen induces demyelination using myelin-specific
antibodies and histological stains that clearly show myelin loss.
Demyelination can be associated with axonal damage in MS and
Alzheimer’s disease50–52. Future studies will show whether
fibrinogen-induced demyelination is primary associated with
preservation of axons, or whether it is accompanied by axonal
damage.
Our results may have broad implications for the potential
development of new therapeutic strategies for neuroinflammatory
diseases. Activation of CD11bþ resident CNS cells appear to be
one of the earliest events leading to local CNS antigen
presentation, amplification of myelin-reactive T-cell responses,
infiltration of peripheral macrophages and axonal
damage5,17,53,54. Since CD11b/CD18 is a pleiotropic receptor55,
specific inhibition of its pathogenic ligand fibrinogen would be a
preferred upstream therapeutic strategy for suppressing the
pathogenic cascade in neuroinflammation over any global
inhibition of CD11b/CD18. Selective disruption of CD11b/
CD18–fibrinogen interface would also be expected to protect
the brain from axonal damage and neurodegeneration5.
Importantly, targeting the interaction of fibrinogen with CD11b
would not affect the beneficial functions of fibrinogen in
haemostasis1,11. Since activation of innate immunity is a
hallmark of neuroimmune and neurodegenerative diseases,
inhibiting the interaction of fibrinogen with CD11b/CD18
could be beneficial not only for suppressing autoimmunity, but
also halting neurodegeneration. Identification of extravascular
fibrinogen as a key regulator of CNS innate and adaptive
immunity might allow us to develop novel therapies targeting
early and late events in neuroinflammatory diseases and
potentially provide new treatment options.
Methods
Mice. C57BL/6 MHC II / (ref. 28), Cxcl10 / (ref. 29), Itgam / (ref. 45),
Cx3cr1GFP/þ (ref. 56), MOG-specific TCR transgenic mice (2D2)31 and SJL/J were
purchased from the Jackson Laboratory. C57BL/6 Fib / (ref. 19), Fibg390–396A
mice22, OVA-specific TCR-transgenic mice (OT-II)32, RAG1 / (ref. 57),
RAG2 / gc / (ref. 30) and Ccr2RFP/RFP mice42 were also used. C57BL/6
Ccr2RFP/RFP mice were crossed with Cx3cr1GFP/GFP mice to generate Cx3cr1GFP/
þCcr2RFP/þ mice. All animal experiments were performed on adult male mice at
10–15 weeks of age. Mice were housed in the groups of five per cage under
standard vivarium conditions and a 12-h light/dark cycle. All animal protocols
were approved by the Committee of Animal Research at the University of
California, San Francisco, and in accord with the National Institutes of Health
guidelines.
Stereotactic injections in the corpus callosum. Mice were anaesthetized with
avertin and placed in a stereotactic apparatus. Plasma plasminogen-free fibrinogen
(Calbiochem) was dissolved in endotoxin-free distilled water (HyClone), diluted to
5mgml 1 with ACSF. Fibrinogen (1 ml of 5mgml 1), ACSF, albumin (1 ml of
5mgml 1) or kininogen (1 ml of 0.1mgml 1) were slowly injected (0.3 ml min 1)
with a 10-ml Hamilton syringe attached to a 33-G needle into the brain at coor-
dinates (anteroposterior,  1.0mm; mediolateral,  1.0mm; dorsoventral,
 1.75mm from the bregma, according to Paxinos and Watson) as described5.
Plasma was isolated and injected as described5.
Intracerebroventricular delivery of antibody. Functional-grade purified anti-
CD11b (M1/70; eBioscience), or isotype control IgG (eBioscience), was injected
(0.2 ml min 1) with a 10-ml syringe attached to a 33-G needle into cerebral
ventricle (anteroposterior,  2.0mm; mediolateral, 0mm, dorsoventral,
 2.0mm) 30min before fibrinogen injection.
Stereotactic injections in the spinal cord. Mice were anaesthetized by intra-
peritoneal injection of ketamine (100mg kg 1) and xylazine (15mg kg 1).
A midline skin incision was made over the upper lumbar regions of spinal cord.
The spinal column was secured via the mouse vertebral clamps fixed in a stereo-
taxic frame. The epidural space was exposed by disruption of the L1–L2
interspinous ligament without laminectomy as described58. A pulled glass
micropipette prefilled with fibrinogen was inserted into the spinal cord at
coordinates (0.3-mm lateral to the spinal midline, a depth of 0.9mm from the
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spinal cord surface). Fibrinogen (1ml of 5mgml 1) was injected (0.2 ml min 1)
and the glass micropipette remained in place for 5min before slowly withdrawn.
After surgery, the muscles and skin were sutured, and mice were allowed to
recover.
Expression of recombinant fibrinogen. For the production of recombinant
fibrinogen, freestyle HEK293T cells were transiently co-transfected with three
eukaryotic expression vectors containing full-length complementary DNA (cDNA)
for the three chains of fibrinogen, alpha (1.9 kb), beta (1.3 kb) and gamma (1.3 kb),
according to the standard procedures. At day 4 post transfection, medium was
collected and the supernatant was passed through a Vivaspin-20 concentrator with
cutoff 100,000 molecular weight cutoff and was added to a Slide-A-Lyzer Dialysis
cassette with cutoff 10,000 molecular weight cutoff for overnight dialysis in PBS
buffer at 40 C with stirring. Expression of the recombinant fibrinogen protein was
evaluated by SDS–polyacrylamide gel electrophoresis gel electrophoresis and
Coomassie staining.
Histology and immunohistochemistry. Mice were transcardially perfused with
4% paraformaldehyde under avertin anaesthesia. Brains and spinal cord were
removed, postfixed, processes for paraffin embedding. Luxol fast blue staining and
immunohistochemistry were performed as described11,59,60. For toluidine blue
staining, animals were intracardially perfused under deep ether anaesthesia with
ice-cold 2% paraformaldehyde, 0.5% glutaraldehyde in 0.1mol l 1 phosphate
buffer, pH 7.2, for 1min, followed by ice-cold 3% glutaraldehyde in 0.1mol l 1
phosphate buffer for 5min. Brains were removed, immersion-fixed for 24 h in
phosphate-buffered 3% glutaraldehyde, postfixed in 2% osmium tetroxide solution
and subsequently embedded in epoxy resin. Semi-thin sections were cut and
stained with toluidine blue. For immunohistochemistry, sections were
permeabilized in 0.1% Triton X-100, blocked with 5% bovine serum albumin and
5% normal donkey serum, and incubated for 24 h at 4 C with primary antibodies.
Primary antibodies were rabbit anti-Iba-1 (1:1,000, Wako), rabbit anti-CD3
(1:1,000, Dako), rabbit anti-GFAP (1:500, Sigma), mouse anti-MBP (1:100,
Covance), rat anti-mouse MHC class II (1:200, BMA Biomedicals) or goat anti-
mouse CXCL10 (1:200, R&D system). Sections were rinsed in PBS with 0.1%
Triton X-100 and incubated with secondary antibodies conjugated with Alexa
Fluor 488 or 594 (1:200, Jackson Immunochemicals) for 1 h in the dark.
Immunohistochemistry using the primary anti-MBP monoclonal antibody was
performed with the MOM kit (Vector) according to the manufacturer’s instruction.
After washing in PBS, sections were mounted on glass slides and coverslipped with
Prolong Gold antifading agent (Invitrogen). Images were acquired using an
Axioplan II epifluorescence microscope (Zeiss) equipped with dry Plan-Neofluar
objectives (10 0.3 numerical aperture (NA), 20 0.5 NA or 40 0.75 NA).
Quantification was performed on thresholded images using ImageJ by blinded
observers.
Flow cytometry. Mice were perfused with saline and brain slices were prepared
using the adult mouse brain slicer matrix (Zivic Instruments). Corpus callosal area
was dissected from the slices and minced tissue was digested using collagenase
IV (Roche) at 37 C for 30min. Cell suspensions were filtered through a 70-mm-cell
strainer (BD Falcon). Cell suspensions were prepared in RPMI-1640 (Invitrogen),
supplemented with 5% (vol/vol) heat-inactivated fetal bovine serum (FBS, Invi-
trogen), 50U penicillin–streptomycin (Invitrogen) and 50 mM b-mercaptoethanol
(Invitrogen). Single-cell suspensions were incubated with Myelin Removal Beads
(Miltenyi Biotec), and cells were collected by autoMACs Pro Separator (Miltenyi
Biotec). Intracellular staining of splenocytes derived from mice undergoing
MOG35–55 EAE5,11 was used as positive control for fluorescence-activated cell
sorting antibody staining. For cytokine analysis, cells were incubated for 4 h with
phorbol 12-myristate 13-acetate (50 ngml 1, Sigma), ionomycin (500 ngml 1,
Sigma) and Golgi-Plug (BD Biosciences) and surface stained with anti-CD3-PE
(eBioscience), anti-CD4-APC-Cy7 (eBioscience) and anti-CD8-PacBlue
(eBioscience). Cells were then fixed with Cytofix/Cytoperm solution (BD
Biosciences), and intracellular cytokine staining was performed with anti-IFN-g-
PE-Cy7 (eBioscience), anti-IL-4-Alexa 647 (eBioscience) and anti-IL-17a-FITC
(eBioscience). All labelled antibodies were used at 1:300 dilutions. Flow cytometric
analysis was performed on an LSR II (BD Biosciences). Data were analysed using
the FlowJo software (Tree Star).
Detection of endogenous MOG antigen-specific T cells. Fibrinogen-injected
brains and its draining lymph nodes were removed at 7 days post injection, and
single-cell suspensions were prepared as described above. Prepared lymphocytes
were stimulated with 20mgml 1 MOG35–55 for 7 days. Endogeneous MOG anti-
gen-specific T cells were identified with MOG35–55-specific T-select I-Ab MOG35–55
tetramer (MBL). I-Ab OVA323–339 Tetramer (MBL) was used as a negative control.
Cultured cells were resuspended in FCM buffer (2% FCS/0.05% NaN3/PBS) and
incubated with FcR-blocking antibody for 5min at room temperature. Cells were
incubated with I-Ab MOG35–55 tetramer for 60min at 4 C followed by anti-CD4-
FITC incubation for 30min at 4 C. After two washes with FCM buffer, cells were
analysed with an LSR II.
T-cell CFSE staining and adoptive transfer. Naive 2D2 CD4þ T cells were
isolated from spleens and lymph nodes of 2D2 mice using CD4þCD62Lþ T-cell
isolation kits (Miltenyi Biotec). Isolated T cells were labelled with CFSE35
(Invitrogen) at room temperature. A total of 1 107 cells were transferred
intraperitoneally into recipient 24 h before ACSF and fibrinogen injection into the
corpus callosum. On day 6, labelled T cells were isolated from the brains, and the
frequency of CFSEþ (CFSElow)TCR-Vb11þCD4þ T cells was analysed by flow
cytometry. For analysis of CNS migratory activity of 2D2 or OT-II CD4þ T cells,
isolated naive 2D2 or OT-II CD4þ T cells were co-cultured 3 days with BMDMs
incubated with either 20mgml 1 MOG35–55 or OVA323–339 peptide together with
or without fibrin. Cells were then labelled with CFDA-SE according to the
manufacturer’s instructions (Invitrogen) and injected (1 107 cells per mouse)
into the Rag1 / recipient mice that had been injected with fibrinogen 2 days
before. Three days after post-T-cell injection, mice were killed, and their brains
were subjected to histological analysis.
Isolation of primary microglia. Microglia were prepared from neonatal rat or
mouse pups at postnatal day (P) 2–3. The cortices were separated from meninges
and minced with a sterile razor blade. Tissue pieces were transferred into 2.5%
Trypsin solution (Life Technologies/Gibco) containing DNAse (SIGMA). After
incubation at 37 C for 25min the trypsin solution was removed, cortices were
washed with 30% FBS in DPBS and serially triturated with 30% FBS in Dulbecco’s
phosphate-buffered saline (DPBS) (Life Technologies/Gibco) containing DNAse.
The cell suspension was gently spun at 200g for 15min and the pellet resuspended
in DMEM (Life Technologies/Gibco), containing 10% FBS (Life Technologies/
Gibco), 100 units per millilitre penicillin and 100mgml 1 streptomycin (Life
Technologies/Gibco). Cells were plated into poly-D-lysine pre-coated T-75 flasks at
a density of 2–3 cortices per flask. On day 3 in vitro, fresh medium was added and
cells were grown for 1 more day. On day 4 in vitro, flasks were placed onto a shaker
platform, preheated to 37 C and microglia cells were shaken off the cortical cell
layer at 200 r.p.m. for 2 h. The medium containing mostly microglia cells was
removed from the flasks and cells were spun at 200g for 15min. The cell pellets
were gently resuspended in culture medium and the microglia density was adjusted
to 5000 cells per microlitre.
Isolation of BMDMs. BMDMs were prepared as described61. In brief, bone
marrow cells were isolated from tibia and femur of 10-week-old mice and cultured
in RPMI-1640 (Invitrogen) supplemented with 10% (vol/vol) heat-inactivated FBS
(Invitrogen), 50U penicillin–streptomycin (Invitrogen), 50 mM b-mercaptoethanol
and murine M-CSF (10 ngml 1). On day 6, adherent BMDMs were harvested
from plates by the addition of PBS containing 5mM EDTA for experiments.
Fibrin stimulation of microglia or BMDMs. To prepare soluble fibrin62, human
plasma fibrinogen (Calbiochem) was converted to fibrin by mixing with thrombin.
Fibrin clots were cut into small pieces and fragmented by sonication. Clot
fragments are filtered through sieves, their concentration was determined, and they
were stored at  80 C. Soluble fibrin preparations were tested for LPS and
thrombin activity and were shown to have undetectable amounts of contaminants.
Cultures were treated with soluble fibrin by adding soluble fibrin to the
supernatant. To prepare fibrin-coated plates, a mixture of thrombin (1Uml 1,
Sigma) and CaCl2 (7mM, Sigma) in HEPES buffer was added into each well of
tissue culture plates (TPP Techno Plastic Products AG, Switzerland) and
subsequently 50mgml 1 of human plasma fibrinogen (Calbiochem) was added.
The plates were incubated for 1 h at 37C. After incubation, solution was
evaporated, and moisture retention was minimized by air flow through the dryer
system. After washing the plates with PBS, microglia or BMDMs were seeded on
fibrin-coated plates. All reagents were made in endotoxin-free water.
T-cell proliferation assay. CD4þ T cells were purified from the spleen with
CD4þCD62Lþ T-cell isolation kits (Miltenyi Biotec). CD4þ T cells were mixed
with BMDM at the ratio (1:5). T-cell proliferation was assessed by BrdU incor-
poration kit (BD Bioscience) during last 24 h of culture. For antigen-specific T-cell
proliferation, CD4þ T cells isolated from 2D2 mice were cultured with MOG35–55
peptide (20mgml 1) for 4 days in the presence of BMDM treated with fibrin or
primary mouse microglia plated on fibrin-coated plates or stimulated with LPS
(200 ngml 1) for 24 h. Cells were then fixed, permeabilized and stained with
FITC-conjugated anti-BrdU (BrdU Flow Kits). For measurement of PLP antigen-
specific CD4þ T-cell proliferation, lymphocytes were isolated from the draining
lymph nodes of SJL/J mice at 7 days after fibrinogen and ACSF injection into the
corpus callosum. Lymphocytes were stimulated with PLP139–151 peptide
(20 mgml 1) and PLP178 191 peptide (20 mgml 1), and IL-2 (10 ngml 1) was
added every 2 days. BrdU incorporation was assessed as described above. For
intracellular cytokine staining, CD4þ T cells were stimulated with 20 mgml 1
MOG35–55 peptide for 72 h and restimulated with PMA and ionomycin for 4 h in
the presence of Golgi-Plug (BD Bioscience), after which IFN-g-, IL-4- and IL-17-
producing cells were analysed by intracellular staining.
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RNA isolation and quantitative PCR. RNA was isolated from brain samples with
the RNAeasy kit (Qiagen), according to the manufacturer’s instructions. RNA was
reverse-transcribed to cDNA using the GeneAmp RNA PCR Core kit (Applied
Biosystems) and random hexamer primers. Real-time PCR analysis was performed
using the Step One Plus (Applied Biosystems) and the Quantitect SYBR Green
PCR kit (Qiagen) with 2 ml of cDNA template in a 25-ml reaction. Results were
analysed using the Opticon 2 Software and the comparative CT method. Data are
expressed as 2A¨A¨CT for the experimental gene of interest normalized to the
housekeeping gene and presented as fold change relative to control. The
gene-specific primers are listed in Supplementary Table 3.
Gene expression profiling by microarray analysis. Microarray analysis was
performed on cultured rat microglia treated with fibrin or BMDMs plated on
fibrin-coated plates and brain tissues from ACSF- and fibrinogen-injected mice.
Rat pups were used to isolate highly pure microglial cultures in sufficient numbers
for microarray analysis. For brain tissue microarray analysis, corpus callosal area
was dissected from brain slices prepared with brain slicer matrix (Zivic instru-
ments). Total RNA was isolated using RNeasy Mini kit/RNeasy Lipid tissue mini
kit (QIAGEN) according to the manufacturer’s instruction. Probes were prepared
using NuGEN Ovation Pico WTA V2 kit and NuGEN Encore Biotin Module, and
hybridized to Rat and Mouse Gene 1.0 ST GeneChip arrays (Affymetrix). Arrays
were scanned using an Affymetrix GCS3000 scanner and Affymetrix Command
Console software, and data were normalized using the RMA algorithm in Affy-
metrix Expression Console. Microarrays were normalized for array-specific effects
using Affymetrix’s ‘Robust Multi-Array’ normalization. Normalized array values
were reported on a log2 scale. For statistical analyses, we removed all array probe
sets where no experimental groups had an average log2 intensity 43.0. This is a
standard cutoff, below which expression is indistinguishable from background
noise. Linear models were fitted for each gene using the Bioconductor ‘limma’
package in R63. Moderated t-statistics, fold change and the associated P values were
calculated for each gene. To account for the fact that thousands of genes were
tested, we reported false discovery rate (FDR)-adjusted values, calculated using the
Benjamini–Hochberg method64. FDR values indicate the expected fraction of
falsely declared, differentially expressed (DE) genes among the total set of declared
DE genes (that is, FDR¼ 0.15 would indicate thatB15% of the declared DE genes
were expected to be due to experimental noise instead of actual differential
expression). The microarray data have been deposited in the Gene Expression
Omnibus (GEO) database accession number GSE71084.
Induction of EAE and systemic fibrinogen depletion. EAE was induced in
8-week-old female SJL/J by subcutaneous immunization with 100 mg PLP139–151
(HSLGKWLGHPDKF; Auspep Pty Ltd) as described11. Mice were depleted of
fibrinogen with ancrod as described11. The mice received 2.4U ancrod per day by
mini-osmotic pump. In control animals, buffer-filled minipumps were implanted.
On day 9 of immunization, draining lymph node T cells were obtained from EAE
mice and cultured with PLP139–151 peptide for the detection of intracellular IFN-g
and IL-4 in CD4þ T cells and BrdU proliferation assay as described above.
Statistical analyses. The data are presented as mean±s.e.m. Statistical calcula-
tions were performed using the GraphsPad Prism. Data distribution was assumed
to be normal, but this was not formally tested. No statistical methods were used to
predetermine sample size, but our sample sizes are similar to those reported
previously5,11,59. Statistical significance was determined with non-parametric two-
sided Mann–Whitney U-test, one-way, or two-way, analysis of variance followed by
Bonferroni post test (multiple comparisons). Mice and cells were divided into
experimental groups in an unbiased manner. No randomization was used to assign
groups or collect data. All animals survived until the end of the study and all data
points were included in analysis. All histopathological analysis was performed by a
blinded observer.
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